• Explore /
  • Poster
  • / Randomized phase II trial of modified (m) FOLFOX6 induction chemotherapy with or without aflibercept before standard chemoradiotherapy (CRT) and total mesorectal excision (TME) in patients with high-risk rectal adenocarcinoma (HRRC): Final results of the GEMCAD 1402, and by molecular subtypes.

Randomized phase II trial of modified (m) FOLFOX6 induction chemotherapy with or without aflibercept before standard chemoradiotherapy (CRT) and total mesorectal excision (TME) in patients with high-risk rectal adenocarcinoma (HRRC): Final results of the GEMCAD 1402, and by molecular subtypes.

Abstract Poster

Authors

null

Carlos Fernandez-Martos

Hospital Quironsalud, Valencia, Spain

Carlos Fernandez-Martos , Isidro Machado , Carles Pericay , Nuria Salas , Jaime Feliu Batlle , Sanne ten Hoorn , Louis Vermeulen , Ferran Losa , Rocio Garcia Carbonero , Vicente Alonso , Ruth Vera , Javier Gallego , Jaume Capdevila , Antonieta Salud , Miguel Nogué , Joan Maurel , Laura Layos , Clara Montagut , Xabier Garcia-Albeniz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Local-Regional Disease

Clinical Trial Registration Number

NCT02340949

Citation

J Clin Oncol 38: 2020 (suppl; abstr 4102)

DOI

10.1200/JCO.2020.38.15_suppl.4102

Abstract #

4102

Poster Bd #

94

Abstract Disclosures

Similar Posters

First Author: Carlos Fernandez-Martos

First Author: Carlos Fernandez-Martos

First Author: Xiao X. Wei

First Author: Elias Chandran